Effect of remimazolam on cardiac repolarization during modified electroconvulsive therapy

Effect of remimazolam on cardiac repolarization during modified electroconvulsive therapy - Remimazolam on cardiac repolarization

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000056673

Enrollment

Registered

2025-04-01

Start date

2025-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia and depression

Interventions

Patients scheduled to undergo mECT will be assigned to group R or group P. In group R: iv remimazolam (12mg/kg/h), after administration of 1 mg/kg succinylcholine, eECT will be performed. The Tpeak-Te

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ASA physical status 1 or 2, aged 20-65 years who are scheduled to undergo modified electroconvulsive therapy will be included. We will receive written informed consent from all patients

Exclusion criteria

Exclusion criteria: 1) We excluded patients with cardiovascular diseases and those with preoperative ECG abnormalities. 2) Patients contraindicated with remimazolam or propofol will be excluded. 3) Patients who are ineligible for this study by medical doctor will be excluded.

Design outcomes

Primary

Measure	Time frame
Tpeak-Tend	—

Secondary

Measure	Time frame
QT-dispersion	—

Countries

Japan

Contacts

Public ContactShouta Katayanagi

Dokkyo Medical University Department of Anesthesiology

takasusu@dokkyomed.ac.jp0282861111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026